attention. Our study was cross-sectional. The 1:1 design allowed the recruitment of a relatively large control population and the confirmation that in both sexes serum OPG normally increases while advancing age. This observation may also be viewed as a counterevidence for disease-related mechanisms accounting for higher levels in MM and MGUS patients as well. Indeed, no previous study included MGUS patients. Interestingly enough, our data do not support the view that circulating OPG reflects its availability in the bone microenvironment. It is currently agreed that OPG gene is expressed by many cell types. OPG levels may come from a number of sources. Vascular expression of OPG is a focus of intense research. Since OPG reportedly acts as an antiapoptotic factor for endothelial cells 7 and angiogenesis was found to be increased in both MGUS and MM microenvironments, increased OPG levels could reflect such processes too. Clearly, much more information on the RANKL/RANK/OPG system in tissutal compartments other than bone are needed before drawing any assumption on the relevance of serum OPG levels to lytic bone disease.
An important point concerns analytical issues. OPG is measurable by immunometric methods that provide ranges of normality remarkably different as a function of different antibody pairs and reagents and preanalytical variables as well, as we and others have previously pointed out. 8 Conceivably, different available reagents recognize different OPG forms.
In conclusion, we found increased OPG levels in both MGUS and MM patients. OPG levels did not correlate with disease stage and skeletal manifestations. Further studies are needed to define the significance of serum levels of OPG in plasma cell disorders. Given a number of unexplored analytical and preanalytical issues, and wide expression of OPG in human tissues, caution must be used in interpreting serum OPG as a marker of myeloma bone disease.
Remission of adult acute lymphocytic leukaemia with Alemtuzumab
Leukemia ( In patients who have relapsed, following a first remission, the probability of cure is almost nil with conventional chemotherapy only. 1 Alemtuzumab (Mab Campath) is a humanized monoclonal antibody directed against the CD52 antigen present on the surface of B and T lymphocytes. It has been initially developed in rats in the early eighties 2 and is currently approved for the second-line treatment of chronic lymphocytic leukaemia. It has been tested successfully in murine models of T-cell leukaemia 3 and in some human lymphoproliferative disorders, 4, 5 but its use in adult ALL has never been reported.
We wish to report on the attainment of a long duration remission with alemtuzumab in an adult patient with B-cell ALL in early relapse.
The patient, a 58-year-old white male, was diagnosed with a nonhypercellular, nontumoral B-cell ALL in May 2002. Blast cells were CD 10 þ , CD19 þ , CD22 þ , CD 79a þ . CD52 was not tested (not present in the routine panel). Chromosome analysis showed a clonal population with the inversion i (7)(q10) in 3/21 mitoses. There was no specific marker by molecular biology, and the bcr-abl transcript was not detected.
The patient was treated according to the French LALA 94 national protocol. 6 Blast disappearance was achieved after a first course combining steroids, daunorubicin vincristine and cyclophosphamide, with however no full normal haemopoiesis recovery. The course was complicated by severe encephalitis attributed to drug toxicity. Three subsequent consolidation courses (rotating agents) were given. The patient had no family donor for an allogeneic stem cell transplantation and failed attempts at mobilizing peripheral blood stem cells in view of an autograft.
On December 2002, he became deeply pancytopenic and a bone marrow aspiration showed an early relapse with 3% blast cells bearing the same immunophenotypical and chromosome abnormalities seen at initial diagnosis. The patient was in poor clinical condition. In view of the previous encephalitis following the first induction course and the absence of full haemopoietic recovery since initial diagnosis, it was decided an attempt with alemtuzumab rather than conventional chemotherapy. From 19 December 2002, the patient received alemtuzumab alone at a dose of 30 mg, 3 days per week for 4 weeks. Blast cells disappeared from the marrow by cytology, immunophenotyping and chromosome analysis. He however remained cytopenic with haemoglobin 9g/dl; leucocytes 700/mm 3 ; platelets 33000/ mm 3 . Erythropoietin and granulocyte-colony stimulating factor (G-CSF) were given.
Alemtuzumab was pursued at a dose of 30 mg 3 days a week, every 2 months. Prophylaxis of infection consisted in valacyclovir, atovaquone, itraconazole and fluconazole p.o. Although the patient had a past history of pulmonary and urogenital tuberculosis, no specific prevention was carried out. There was no infectious complication and the patient resumed normal professional activity. After the third course, alemtuzumab administration was constantly followed by generalized erythroderma peaking on day 15 following first infusion and fading away spontaneously (no steroids) at time of next course. A marrow aspiration in September 2003 was normal. On 1 May 2004, 16 months after beginning alemtuzumab treatment, the patient is disease free but cytopenic (haemoglobin 12.5 g/dl; neutrophils 1900/mm 3 ; platelets 95000/mm 3 ) with a profound lymphopenia (145/mm 3 ). Alemtuzumab is here reported as having controlled B-ALL blast cells for more than a year in an adult patient who relapsed on therapy within 6 months. This observation may be of importance in indicating a potential role for alemtuzumab in the treatment of adult ALL. We however cannot rule out an additional effect of the cytokines administered in association for maintenance, since the main tumor killing mechanism with alemtuzumab in vivo involves FcR gamma III receptors on the surface of polymorphonuclear leucocytes, which mediate antibody-dependant cellular cytotoxicity. 3 Either alemtuzumab alone or alemtuzumab and G-CSF should be tested further. 
